Hong Kong Connect Flows: Tencent, Meituan, Wuxi Biologics, Kintor
We highlight Hong Kong Connect inflows into Tencent Holdings Limited (700 HK), Meituan (3690 HK), and outflows from Wuxi Biologics (2269 HK).
330 Views
Kintor Pharmaceutical (9939 HK) – Dual Play on COVID and Solid Tumors
Kintor Pharma is set to fly high ahead of its first product launch in China for prostate cancer, which has high unmet medical need. COVID-19...
553 Views
Pre-IPO Yonghe Medical Group - Here Are the Concerns
The article analyzed Yonghe Medical Group in terms of the concerns and challenges that deserve investors’ attention,including the business...
717 Views
HSCI Index Rebalance & Stock Connect: Expected Changes in September
Currently we see 28 potential inclusions & 22 deletions from the HSCI at the Sep rebalance. Most of the inclusions will join Stock Connect while...
824 Views
Kintor Pharma (开拓药业) Placement - Still Riding the COVID Momentum
Kintor Pharmaceutical (9939 HK) is looking to raise up to a total of US$183m in its concurrent top-up and secondary placement.
418 Views